GlassScriptPhysician profile
James S Evans
NPI 1295721413
$4,621.86
in general payments reported to CMS, 2019-2025
19 companies · $1,452 in 2025
The $1,452 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $265 · 2021: $350 · 2022: $574 · 2023: $12.96 · 2024: $1,500 · 2025: $1,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,824 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,823.81 |
| Education | $141.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,174.16 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Abbvie INC. | $1,168.10 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $586.87 | 2024-2025 | Acthar |
| Janssen Biotech, INC. | $553.90 | 2022-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $300.64 | 2019-2025 | |
| Radius Health, INC. | $203.49 | 2024-2025 | Tymlos |
| Regeneron Healthcare Solutions, INC. | $100.55 | 2024-2025 | Dupixent |
| Glaxosmithkline, LLC. | $94.35 | 2022-2025 | Benlysta |
| Biocon Biologics INC | $87.76 | 2024-2025 | Hulio, Yesintek |
| Astrazeneca Pharmaceuticals LP | $71.62 | 2024-2025 | Saphnelo |
| Takeda Pharmaceuticals U.S.A., INC. | $71.01 | 2025 | Entyvio |
| Genzyme Corporation | $43.92 | 2024 | |
| Almatica Pharma LLC | $34.92 | 2024 | Teriparatide |
| Janssen Scientific Affairs, LLC | $30.13 | 2022 | |
| Medtronic Vascular, INC. | $25.28 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $23.04 | 2024 | Taltz |
| Boston Scientific Corporation | $18.32 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $17.30 | 2024 | Uptravi, Opsumit |
| Aimmune Therapeutics, INC. | $16.50 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.